Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

  • Van Emburgh, Beth O.
  • Vidal Barrull, Joana
  • Bellosillo Paricio, Beatriz
  • Albanell Mestres, Joan
  • Montagut Viladot, Clara
  • Bardelli, Alberto
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies, This study was supported by European Community’s Seventh Framework Programme under grant agreement no. 602901 MErCuRIC (A.B. and F.D.N.); European Community’s Seventh Framework Programme under grant agreement no. 635342-2 MoTriColor (A.B. and S.S.); TRANSCAN-2 JTC 2014 contract no. TRS-2015-00000060 INTRACOLOR (S.A.); IMI contract no. 115749 CANCER-ID (A.B.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project no. 9970 Extension program (A.B. and S.S.); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A.B.); AIRC IG no. 16788 (A.B.); AIRC and the EU under a Marie Curie COFUND (G.G.); Fondo per la Ricerca Locale (ex 60%), Universita` di Torino, 2014 (F.D.N.); Instituto de Salud Carlos III, organismo adscrito al Ministerio de Economía y Competitividad and ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’ grants PI15/00457 and DTS15/00048 (C.M.); PIE15/00008 and PI15/00146 (J.A.); RETIC Cancer–Instituto de Salud Carlos III RD12/0036/0051 (C.M. and J.A.); 2014SGR740 (J.A.); and Xarxa de Banc de Tumors de Catalunya and Fundació Cellex (C.M.). Investigators at Niguarda Cancer Centers are supported by the grants Terapia Molecolare dei Tumori (A.S.-B. and S.S.) and Dynamic of Tumor Evolution & Therapy (A.S.-B.) from Fondazione Oncologia Niguarda Onlus.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

  • Lanuza, Pilar M.
  • Alonso Aguado, Maria Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García Mulero, Sandra
  • Arnau, Raquel
  • Santos, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo Cid, Roberto
  • Agustin Ferrández, M. Jose
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez, Eva M.
  • Ramírez Labrada, Ariel
  • Arias, Maykel
  • Sanz Pamplona, Rebeca
  • Pardo, Julián
BackgroundColorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. MethodsNK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. ResultsHLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA(+) and HLA(-) CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. ConclusionsOur results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Adoptive NK cell transfer as a treatment in colorectal cancer patients: analyses of tumour cell determinants correlating with efficacy in vitro and in vivo

  • Lanuza, Pilar M.
  • Alonso, M. Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García-Mulero, Sandra
  • Arnau, Raquel
  • Santos Vivas, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo-Cid, Roberto
  • Agustín Ferrández, M. J.
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez Buerba, Eva Mª
  • Ramírez-Labrada, Ariel
  • Arias, Maykel
  • Sanz-Pamplona, Rebeca
  • Pardo, Julián
6 figures., [Background]: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC., [Methods]: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity., [Results]: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA− CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control., [Conclusions]: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy., Work in the JP laboratory is funded by ASPANOA, CIBER (CB 2021; Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación and Union Europea.NextGenerationEU), Fundacion Inocente, Carrera de la Mujer Monzón, FEDER/Gobierno de Aragón (Group B29_17R), and Ministerio de Ciencia, Innovación e Universidades (MCNU), Agencia Estatal de Investigación (SAF2017‐83120‐C2‐1‐R and PID2020-113963RB-I00). Predoctoral grants/contracts from Gobierno de Aragon (IU-M and JP) are supported by ARAID Foundation. EG is funded by Ministerio de Ciencia, Innovación y Universidades (MCNU), and Agencia Estatal de Investigación (PID2020-113963RB-I00). MA and LS are funded by Postdoctoral Juan de la Cierva Contract. SR, LC, SH, and IU-M are funded by predoctoral contracts from Aragon Government. PL is funded by FPU predoctoral grants from Ministerio de Ciencia, Innovación e Universidades. Work at the Catalan Institute of Oncology is funded by the entity, the Instituto de Salud Carlos III and Ministerio de Economia y Competitividad, and co-funded by FEDER funds—a way to build Europe (PI20/00767), CIBERESP (grant CB07/02/2005), H2020 grant MoTriColor, and the Agency for Management of University and Research Grants (AGAUR) of the Catalan Government grant 2017SGR723. This work is supported by COST Action CA17118., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publication Artículo científico (JournalArticle)

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

  • Lanuza, P. M.
  • Alonso, M. H.
  • Hidalgo, S.
  • Uranga-Murillo, I.
  • García-Mulero, S.
  • Arnau, R.
  • Santos, C.
  • Sanjuan, X.
  • Santiago, L.
  • Comas, L.
  • Redrado, S.
  • Pazo-Cid, R.
  • Agustin-Ferrández, M. J.
  • Jaime-Sánchez, P.
  • Pesini, C.
  • Gálvez, E. M.
  • Ramírez-Labrada, A.
  • Arias, M.
  • Sanz-Pamplona, R.
  • Pardo Jimeno, J.
Background: Colorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. Methods: NK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. Results: HLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA+ and HLA- CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. Conclusions: Our results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy. Copyright © 2022 Lanuza, Alonso, Hidalgo, Uranga-Murillo, García-Mulero, Arnau, Santos, Sanjuan, Santiago, Comas, Redrado, Pazo-Cid, Agustin-Ferrández, Jaime-Sánchez, Pesini, Gálvez, Ramírez-Labrada, Arias, Sanz-Pamplona and Pardo.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

  • Sartore-Bianchi, Andrea
  • Ciardello, Fortunato
  • Erika, Martinelli
  • Muñoz, Susana
  • García-Galera, E.
  • Piris-Giménez, Alejandro
  • Chavarria, Elena
  • SIENA, SALVATORE
  • Ros, Javier
  • Gros, Alena
  • Dienstmann, Rodrigo
  • Tabernero, Josep
  • Elez, Elena
Angiogenesis inhibitors; Immune checkpoint inhibitors; Immunotherapy, Inhibidors de l'angiogènesi; Inhibidors de punts de control immunitari; Immunoteràpia, Inhibidores de la angiogénesis; Inhibidores de puntos de control inmunitario; Inmunoterapia, Background: The use of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) remains limited to tumors harboring microsatellite instability (MSI); however, a subset of microsatellite stable (MSS) tumors features an MSI-like phenotype that could predict responses to ICIs combined with anti-angiogenesis agents. Patients and methods: In this single-arm phase II trial, 45 mCRC patients with a positive tumoral MSI-like gene expression signature (GES) progressing to at least one chemotherapy regimen were recruited from seven European sites within the MoTriColor framework. Of these, 24 and 21 were MSI and MSS, respectively, by standard assays. Patients received intravenous atezolizumab (1200 mg) plus bevacizumab (7.5 mg/kg) infusions in 21-day cycles until progression, unacceptable toxicity, or consent withdrawal. The main outcome measure was the objective response rate (ORR, RECIST 1.1). Results: The median (interquartile range) age of participants was 63 (58-73) years, 51.1% were male, 60.0% had right-sided tumors, and 31.1% had liver metastases. The ORR in the whole (MSI-like) sample was 38.6% [95% confidence interval (CI) 24.4% to 54.5%]. Among patients with MSI and MSS tumors, the ORR was 65.2% (95% CI 42.7% to 83.6%) and 9.5% (95% CI 1.2% to 30.4%), respectively. In the MSS subgroup without liver metastasis, the ORR was 15.4% (95% CI 1.9% to 45.4%). Overall median progression-free survival was 6.4 (95% CI 4.1-21.2) months (23.2 and 4.0 months in patients with MSI and MSS tumors, respectively). Grade ≥3 adverse events related to atezolizumab and bevacizumab occurred in 5 (11.1%) and 10 patients (22.2%), respectively. There were two grade 5 adverse events, of which one (colonic hemorrhage) was related to bevacizumab. Conclusions: MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status., This work was supported by the European Commission’s Horizon 2020 Research and Innovation Program [grant number 635342]; the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program (TARGET) [grant number 101020342] to AB; the AIRC under 5 per Mille 2018 program for principal investigator AB [grant number 21091]; the FPRC under 5 per Mille Ministerio della Salute 2022 CARESS for SA; the IMI contract ID: 101007937 PERSIST-SEQ (to AB); the AIRC under IG 2023 for principal investigator AB [grant number 28922] and SA [grant number 29286]; the Italian Ministry of Health—Ricerca Corrente 2025 (to SA); and PRIN 2022—Prot. 2022CHB9BA financed by the European Union—Next Generation EU (to AB). In addition, F. Hoffmann-La Roche Ltd. (no grant number) provided the study medication and partial funding for logistical issues. The funders did not have any direct corporate role in the design, analysis, interpretation of results, or preparation of the manuscript.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer

  • Van Emburgh, Beth O.
  • Vidal Barrull, Joana
  • Bellosillo Paricio, Beatriz
  • Albanell Mestres, Joan
  • Montagut Viladot, Clara
  • Bardelli, Alberto
Blockade of the epidermal growth factor receptor (EGFR) with the monoclonal antibodies cetuximab or panitumumab is effective in a subset of colorectal cancers (CRCs), but the emergence of resistance limits the efficacy of these therapeutic agents. At relapse, the majority of patients develop RAS mutations, while a subset acquires EGFR extracellular domain (ECD) mutations. Here we find that patients who experience greater and longer responses to EGFR blockade preferentially develop EGFR ECD mutations, while RAS mutations emerge more frequently in patients with smaller tumour shrinkage and shorter progression-free survival. In circulating cell-free tumour DNA of patients treated with anti-EGFR antibodies, RAS mutations emerge earlier than EGFR ECD variants. Subclonal RAS but not EGFR ECD mutations are present in CRC samples obtained before exposure to EGFR blockade. These data indicate that clonal evolution of drug-resistant cells is associated with the clinical outcome of CRC patients treated with anti-EGFR antibodies, This study was supported by European Community’s Seventh Framework Programme under grant agreement no. 602901 MErCuRIC (A.B. and F.D.N.); European Community’s Seventh Framework Programme under grant agreement no. 635342-2 MoTriColor (A.B. and S.S.); TRANSCAN-2 JTC 2014 contract no. TRS-2015-00000060 INTRACOLOR (S.A.); IMI contract no. 115749 CANCER-ID (A.B.); AIRC 2010 Special Program Molecular Clinical Oncology 5 per mille, Project no. 9970 Extension program (A.B. and S.S.); Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011 Ministero della Salute (A.B.); AIRC IG no. 16788 (A.B.); AIRC and the EU under a Marie Curie COFUND (G.G.); Fondo per la Ricerca Locale (ex 60%), Universita` di Torino, 2014 (F.D.N.); Instituto de Salud Carlos III, organismo adscrito al Ministerio de Economía y Competitividad and ‘Fondo Europeo de Desarrollo Regional (FEDER), una manera de hacer Europa’ grants PI15/00457 and DTS15/00048 (C.M.); PIE15/00008 and PI15/00146 (J.A.); RETIC Cancer–Instituto de Salud Carlos III RD12/0036/0051 (C.M. and J.A.); 2014SGR740 (J.A.); and Xarxa de Banc de Tumors de Catalunya and Fundació Cellex (C.M.). Investigators at Niguarda Cancer Centers are supported by the grants Terapia Molecolare dei Tumori (A.S.-B. and S.S.) and Dynamic of Tumor Evolution & Therapy (A.S.-B.) from Fondazione Oncologia Niguarda Onlus.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo

  • Lanuza, Pilar M.
  • Alonso Aguado, Maria Henar
  • Hidalgo, Sandra
  • Uranga Murillo, Iratxe
  • García Mulero, Sandra
  • Arnau, Raquel
  • Santos, Cristina
  • Sanjuan, Xavier
  • Santiago, Llipsy
  • Comas, Laura
  • Redrado, Sergio
  • Pazo Cid, Roberto
  • Agustin Ferrández, M. Jose
  • Jaime Sánchez, Paula
  • Pesini, Cecilia
  • Gálvez, Eva M.
  • Ramírez Labrada, Ariel
  • Arias, Maykel
  • Sanz Pamplona, Rebeca
  • Pardo, Julián
BackgroundColorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. MethodsNK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. ResultsHLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA(+) and HLA(-) CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. ConclusionsOur results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

  • Siena, S.
  • Sartore-Bianchi, A.
  • García-Carbonero, Rocío|||0000-0002-3342-397X
  • Karthaus, M.
  • Smith, D.
  • Tabernero, Josep|||0000-0002-2495-8139
  • Van Cutsem, E.
  • Guan, X.
  • Boedigheimer, M.
  • Ang, A.
  • Twomey, B.
  • Bach, B. A.
  • Jung, A. S.
  • Bardelli, Alberto
Mutations in rat sarcoma (RAS) genes may be a mechanism of secondary resistance in epidermal growth factor receptor inhibitor-treated patients. Tumor-tissue biopsy testing has been the standard for evaluating mutational status; however, plasma testing of cell-free DNA has been shown to be a more sensitive method for detecting clonal evolution. Archival pre- and post-treatment tumor biopsy samples from a phase II study of panitumumab in combination with irinotecan in patients with metastatic colorectal cancer (mCRC) that also collected plasma samples before, during, and after treatment were analyzed for emergence of mutations during/post-treatment by next-generation sequencing and BEAMing. The rate of emergence of tumor tissue RAS mutations was 9.5% by next-generation sequencing (n = 21) and 6.3% by BEAMing (n = 16). Plasma testing of cell-free DNA by BEAMing revealed a mutant RAS emergence rate of 36.7% (n = 39). Exploratory outcomes analysis of plasma samples indicated that patients who had emergent RAS mutations at progression had similar median progression-free survival to those patients who remained wild-type at progression. Serial analysis of plasma samples showed that the first detected emergence of RAS mutations preceded progression by a median of 3.6 months (range, -0.3 to 7.5 months) and that there did not appear to be a mutant RAS allele frequency threshold that could predict near-term outcomes. This first prospective analysis in mCRC showed that serial plasma biopsies are more inclusive than tissue biopsies for evaluating global tumor heterogeneity; however, the clinical utility of plasma testing in mCRC remains to be further explored. NCT00891930.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Efficacy and safety of atezolizumab plus bevacizumab in MSI-like metastatic colorectal cancer: a multicenter, single-arm, phase II, open-label clinical trial

  • Sartore-Bianchi, Andrea
  • Ciardello, Fortunato
  • Erika, Martinelli
  • Muñoz, Susana
  • García-Galera, E.
  • Piris-Giménez, Alejandro
  • Chavarria, Elena
  • SIENA, SALVATORE
  • Ros, Javier
  • Gros, Alena
  • Dienstmann, Rodrigo
  • Tabernero, Josep
  • Elez, Elena
Angiogenesis inhibitors; Immune checkpoint inhibitors; Immunotherapy, Inhibidors de l'angiogènesi; Inhibidors de punts de control immunitari; Immunoteràpia, Inhibidores de la angiogénesis; Inhibidores de puntos de control inmunitario; Inmunoterapia, Background: The use of immune checkpoint inhibitors (ICIs) in metastatic colorectal cancer (mCRC) remains limited to tumors harboring microsatellite instability (MSI); however, a subset of microsatellite stable (MSS) tumors features an MSI-like phenotype that could predict responses to ICIs combined with anti-angiogenesis agents. Patients and methods: In this single-arm phase II trial, 45 mCRC patients with a positive tumoral MSI-like gene expression signature (GES) progressing to at least one chemotherapy regimen were recruited from seven European sites within the MoTriColor framework. Of these, 24 and 21 were MSI and MSS, respectively, by standard assays. Patients received intravenous atezolizumab (1200 mg) plus bevacizumab (7.5 mg/kg) infusions in 21-day cycles until progression, unacceptable toxicity, or consent withdrawal. The main outcome measure was the objective response rate (ORR, RECIST 1.1). Results: The median (interquartile range) age of participants was 63 (58-73) years, 51.1% were male, 60.0% had right-sided tumors, and 31.1% had liver metastases. The ORR in the whole (MSI-like) sample was 38.6% [95% confidence interval (CI) 24.4% to 54.5%]. Among patients with MSI and MSS tumors, the ORR was 65.2% (95% CI 42.7% to 83.6%) and 9.5% (95% CI 1.2% to 30.4%), respectively. In the MSS subgroup without liver metastasis, the ORR was 15.4% (95% CI 1.9% to 45.4%). Overall median progression-free survival was 6.4 (95% CI 4.1-21.2) months (23.2 and 4.0 months in patients with MSI and MSS tumors, respectively). Grade ≥3 adverse events related to atezolizumab and bevacizumab occurred in 5 (11.1%) and 10 patients (22.2%), respectively. There were two grade 5 adverse events, of which one (colonic hemorrhage) was related to bevacizumab. Conclusions: MSI-like GES does not identify a population with higher sensitivity to immune checkpoint plus angiogenesis inhibition. However, responses are promising in patients with MSI tumors and, to a lesser extent, in patients without liver metastasis regardless of MSI status., This work was supported by the European Commission’s Horizon 2020 Research and Innovation Program [grant number 635342]; the European Research Council (ERC) under the European Union’s Horizon 2020 Research and Innovation Program (TARGET) [grant number 101020342] to AB; the AIRC under 5 per Mille 2018 program for principal investigator AB [grant number 21091]; the FPRC under 5 per Mille Ministerio della Salute 2022 CARESS for SA; the IMI contract ID: 101007937 PERSIST-SEQ (to AB); the AIRC under IG 2023 for principal investigator AB [grant number 28922] and SA [grant number 29286]; the Italian Ministry of Health—Ricerca Corrente 2025 (to SA); and PRIN 2022—Prot. 2022CHB9BA financed by the European Union—Next Generation EU (to AB). In addition, F. Hoffmann-La Roche Ltd. (no grant number) provided the study medication and partial funding for logistical issues. The funders did not have any direct corporate role in the design, analysis, interpretation of results, or preparation of the manuscript.